Apollon Formularies Plc - Resignation of Non-Executive Director
Announcement provided byApollon Formularies plc · APOL
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a
Nick has sat on the Board of Apollon since it went public on the Aquis Growth market in April 2021.
Nick Ingrassia, of Apollon Formularies, commented "It has been an honour and a pleasure to serve on the Apollon board alongside a group of such brilliant and dedicated directors. I believe Apollon has built an exciting intellectual property portfolio and brand. With a renewed outlook following its geographic shift, I believe the business is well positioned for success despite the challenging market environment in the medical cannabis space."
Stene Jacobs, COO of Apollon Formularies, commented,"We extend our heartfelt appreciation to Nick for his service and dedication during his tenure as a valued member of our board. While we understand and respect his decision to step down, his impact will continue to resonate in our ongoing business. We extend our best wishes for his future endeavours."
The Directors of the Company accept responsibility for the contents of this announcement.
- End -
Stene Jacobs email@example.com
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller firstname.lastname@example.org
Blytheweigh (Financial PR/IR-
Tel: +44 207 138 3204
Tim Blythe email@example.com
Megan Ray firstname.lastname@example.org
About Apollon Formularies plc
Apollon Formularies is an international bio-medical pharmaceutical company specialising in cutting edge research and treatment of patients with cancer and chronic pain.
Apollon is federally legal, licensed in
Apollon is a publicly traded company listed on the Aquis Growth Market in
View more ...